About 3,300 women a year may benefit from decision to approve ribociclib
Women with incurable advanced breast cancer will be able to get a drug from the NHS that can potentially extend their life by almost eight months, under new guidance.
The National Institute for Health and Care Excellence (Nice) has approved the drug – ribociclib , also known as Kisqali – for routine use by the NHS in England and Wales. It said around 3,300 women a year with advanced breast cancer could benefit from the decision.
